Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases

This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study. And the independent review committee (IRC) will be formed to monitor efficacy data through the study.

Trial Details

NCT ID
NCT06278454
Phase
PHASE1
Sponsor
Chengdu New Radiomedicine Technology Co. LTD.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • NRT6008 Injection + Systematic chemotherapy
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Suzhou, Jiangsu, China|31.30408,120.59538
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Chongqing, China|29.56026,106.55771

Key Eligibility Criteria

  • Aged ≥18 years and ≤80 years, able to comprehend and sign an informed consent form;
  • Diagnosed with pancreatic adenocarcinoma confirmed histologically or cytologically;
  • Evaluated as unresectable LAPC or metastatic pancreatic cancer with lymph node metastasis only, as determined by the investigator; or having contra…
  • ECOG performance status score ≤1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →